• CA-074: Documented Cathepsin B Inhibition

  2026-10-20

  CA-074 (SKU A1926) is described by ApexBio as a selective cathepsin B inhibitor whose active-site binding blocks proteolytic activity. The supplier links this mechanism to research on neurotoxicity, immune response modulation, and cancer metastasis, while emphasizing that the supplied evidence is product information rather than an independently assessed matched paper.

• What an SREBP Drug Screen Really Established

  2026-10-19

  Ishida and colleagues developed a lipid-dependence-based screen for FDA-approved compounds and identified 13 drugs that suppressed SREBP-associated responses in cancer-cell models. The study is important as a screening and target-hypothesis framework, but its results do not establish direct SREBP binding, clinical anticancer activity, or equivalence between the screened collection and the separately marketed DiscoveryProbe™ FDA-approved Drug Library.

• AM580: A Source-Bounded RARα Agonist Overview

  2026-10-19

  AM580 is described by APExBIO as a selective RARα agonist associated with retinoid-responsive transcription, cellular growth suppression, apoptosis-related readouts, and reduced tumor growth in a named mouse model. Because the available evidence is supplier documentation rather than an identity-matched publication, the potency values, causal mechanism, combination effects, and translational relevance remain bounded by missing assay details, comparators, sample sizes, and uncertainty estimates.

• Visomitin (SKQ1): Evidence and Scope

  2026-10-18

  The APExBIO product description identifies Visomitin, also called SKQ1, as a mitochondria-targeted antioxidant associated with mitochondrial ROS and oxidative-stress research. That description supports a documented identity and proposed mechanism, but it does not provide matched experimental evidence, assay results, comparators, effect sizes, or clinical validation.

• Mouse Lung Organoid Kit: Evidence and Scope

  2026-10-17

  The APExBIO Mouse Lung Organoid Kit (SKU K2940) is identifiable as a product intended for a mouse lung organoid research context, but the available product information does not document its composition, molecular mechanism, readouts, validation data, or study-specific performance. No identity-matched research paper is available, so interpretation must remain limited to product identity and the general conceptual role implied by the name.

• ICI 118,551 Hydrochloride: Evidence Scope

  2026-10-16

  The APExBIO listing identifies ICI 118,551 hydrochloride as catalog item B1004, but the available product information contains no description, structural confirmation, mechanism statement, assay context, or identity-matched research evidence. This article therefore separates catalog identity from pharmacological claims and defines what cannot be concluded from the available record.

• How ATRA Reverses Cisplatin-Linked PARP Resistance

  2026-10-16

  Mei and colleagues reported that all-trans retinoic acid reduced molecular features associated with cisplatin-linked niraparib resistance in epithelial ovarian cancer models. The study supports a mechanistic hypothesis involving ALDH1A1, NAMPT, PARP1, checkpoint kinase 1, and NAD+ metabolism, but its preclinical design does not establish clinical efficacy, formal drug synergy, or applicability across defined BRCA or homologous-recombination subgroups.

• DiscoveryProbe Library: What the Evidence Supports

  2026-10-15

  The APExBIO DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is described as a 2,320-compound collection of clinically approved or pharmacopeia-listed bioactive molecules spanning multiple pharmacological classes. Its documented value is as a broad perturbation resource for conceptual drug repositioning screening and target-hypothesis generation; no identity-matched study, product-specific outcome, or comparative performance evidence is available here.

• CA-074: Mechanism, Product Identity, and Evidence

  2026-10-15

  CA-074 is described by APExBIO as a selective cathepsin B inhibitor whose reported biochemical potency and downstream effects span neurotoxicity, immune response modulation, and cancer metastasis models. Because no identity-matched research paper is available here, these claims should be interpreted as supplier-reported evidence rather than an independently verified literature record. The product description supports a mechanistic hypothesis, but it does not establish universal selectivity, clinical benefit, or causal attribution of every model-level outcome to cathepsin B.

• DiscoveryProbe™ FDA-Approved Library: Scope and Evidence

  2026-10-14

  APExBIO describes the DiscoveryProbe™ FDA-approved Drug Library (SKU L1021) as a 2,320-compound FDA-approved bioactive compound library spanning multiple pharmacological classes. The documentation supports a product-identity and scope overview, but not claims of screening performance, target discovery, or therapeutic efficacy: no identity-matched study, readout, comparator, sample size, or outcome statistics are provided.

• Angiopoietin–PEDF Signaling in Retinal Survival

  2026-10-14

  Younis and colleagues report an in vitro pathway in which Müller-cell angiopoietin signaling influences PEDF production and retinal neuronal survival. The findings support a glia-mediated mechanism, but they do not establish clinical neuroprotection or show that BAY-826 was used in the study. Supplier-reported potency for BAY-826 therefore should not be treated as evidence of activity, selectivity, or therapeutic relevance in these retinal models.

• What SLEV Helicase Structures Actually Show

  2026-10-13

  The reported SLEV helicase structure provides a mechanistic framework for target identification, but its docked compounds remain computational leads rather than validated antivirals. The study’s main limitations include modeled rather than experimentally resolved RNA binding, isolated-enzyme evidence, and no demonstrated cellular, animal, or clinical efficacy.

• Foxp1, Notch and CKD Valvular Calcification

  2026-10-13

  A 2026 preclinical study links endothelial Foxp1 to reduced chronic kidney disease–associated valvular calcification through suppression of Jagged-1/Notch signaling, endothelial-to-mesenchymal transition and downstream osteogenic activity. The findings are mechanistically suggestive but remain limited by their mouse-model and gain-of-function design, with no evidence in the supplied record that Parathyroid hormone (1-34) (human) was used in the study.

• CA-074 and Cathepsin B in Necroptosis Research

  2026-10-12

  Recent mechanistic work places cathepsin B downstream of MLKL-driven lysosomal membrane permeabilization during necroptosis. CA-074 is described by APExBIO as a selective cathepsin B inhibitor, but the supplied study does not establish that CA-074 was used, so its findings should not be transferred directly to this compound or to therapeutic settings.

• GANT61 and the GLI2–PRDX1 Ferroptosis Axis

  2026-10-12

  GANT61 is a research small molecule described by APExBIO as a GLI1/GLI2 antagonist, but the supplied bladder-cancer study does not identify GANT61 as the inhibitor used. That study reports a GLI2–PRDX1 regulatory axis associated with ferroptosis resistance and cisplatin sensitivity in bladder-cancer models. The findings are mechanistically informative but remain preclinical and do not establish clinical efficacy for GANT61 or other GLI inhibitors.

8075 records 1/539 page Next 12345 下5页 Last page